(IRON) Disc Medicine - Ratings and Ratios
Red, Blood, Iron, Drug, Clinical
Description: IRON Disc Medicine August 09, 2025
Disc Medicine Inc. (NASDAQ:IRON) is a biotechnology company listed on the NASDAQ stock exchange, categorized under the biotechnology sub-industry. As a common stock, IRON represents ownership in the company.
The companys market capitalization stands at approximately $2.045 billion USD, indicating its size and investor recognition. Notably, the stock has a beta of 2.496, suggesting that its price movements are more volatile than the overall market, which could be attributed to the inherent risks associated with the biotechnology sector.
With a return on equity (RoE) of -22.61%, Disc Medicine is currently operating at a loss, which is not uncommon for companies in the biotechnology industry that are often in the development phase and not yet profitable. The absence of a price-to-earnings (P/E) ratio further indicates that the company is not generating positive earnings.
Key economic drivers for Disc Medicine include the success of its pipeline products, particularly those in clinical development, and the overall demand for its potential therapies. Key performance indicators (KPIs) to watch include clinical trial progress, regulatory approvals, and eventual commercialization of its products. The companys ability to manage its cash burn rate and secure funding will also be crucial in determining its financial health and ability to achieve its development goals.
Investors should closely monitor updates on the companys clinical trials, partnerships, and financial management as these factors will significantly influence the stocks performance. The biotechnology sector is known for its high-risk, high-reward nature, and Disc Medicines stock is likely to be sensitive to news and developments related to its pipeline and financials.
IRON Stock Overview
| Market Cap in USD | 3,223m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2020-08-12 |
IRON Stock Ratings
| Growth Rating | 25.3% |
| Fundamental | 33.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 23.2% |
| Analyst Rating | 4.73 of 5 |
IRON Dividends
Currently no dividends paidIRON Growth Ratios
| Growth Correlation 3m | 93.9% |
| Growth Correlation 12m | 14.8% |
| Growth Correlation 5y | -36% |
| CAGR 5y | 17.42% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.26 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.64 |
| Sharpe Ratio 12m | 0.70 |
| Alpha | 47.77 |
| Beta | 2.504 |
| Volatility | 56.13% |
| Current Volume | 371.8k |
| Average Volume 20d | 371.8k |
| Stop Loss | 81.1 (-5.8%) |
| Signal | 1.28 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM) |
| FCFTA -0.20 (>2.0%) and ΔFCFTA -5.81pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.20 (>3.0%) and CFO -134.2m > Net Income -145.4m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 32.11 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (35.0m) change vs 12m ago 36.55% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 0.0% (prev 0.0%; Δ 0.0pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -56.10 (EBITDA TTM -133.3m / Interest Expense TTM 2.38m) >= 6 (WARN >= 3) |
Altman Z'' -5.09
| (A) 0.96 = (Total Current Assets 661.6m - Total Current Liabilities 20.6m) / Total Assets 665.1m |
| (B) -0.58 = Retained Earnings (Balance) -387.3m / Total Assets 665.1m |
| (C) -0.23 = EBIT TTM -133.5m / Avg Total Assets 587.6m |
| (D) -7.60 = Book Value of Equity -387.1m / Total Liabilities 50.9m |
| Total Rating: -5.09 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 33.30
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -5.21% = -2.60 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.05 = 2.50 |
| 5. Debt/Ebitda 0.72 = 2.11 |
| 6. ROIC - WACC (= -38.65)% = -12.50 |
| 7. RoE -26.60% = -2.50 |
| 8. Revenue Trend data missing |
| 9. EPS Trend 25.84% = 1.29 |
What is the price of IRON shares?
Over the past week, the price has changed by -1.77%, over one month by +24.22%, over three months by +43.94% and over the past year by +47.74%.
Is Disc Medicine a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of IRON is around 78.20 USD . This means that IRON is currently overvalued and has a potential downside of -9.13%.
Is IRON a buy, sell or hold?
- Strong Buy: 8
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the IRON price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 110.3 | 28.1% |
| Analysts Target Price | 110.3 | 28.1% |
| ValueRay Target Price | 92.4 | 7.3% |
IRON Fundamental Data Overview November 04, 2025
P/B = 3.7281
Beta = 2.504
Revenue TTM = 0.0 USD
EBIT TTM = -133.5m USD
EBITDA TTM = -133.3m USD
Long Term Debt = 28.7m USD (from longTermDebt, last quarter)
Short Term Debt = 1.26m USD (from shortTermDebt, last quarter)
Debt = 30.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -96.4m USD (from netDebt column, last quarter)
Enterprise Value = 2.60b USD (3.22b + Debt 30.9m - CCE 650.0m)
Interest Coverage Ratio = -56.10 (Ebit TTM -133.5m / Interest Expense TTM 2.38m)
FCF Yield = -5.21% (FCF TTM -135.6m / Enterprise Value 2.60b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 125.0k) / Revenue TTM)
Tobins Q-Ratio = 3.92 (Enterprise Value 2.60b / Total Assets 665.1m)
Interest Expense / Debt = 2.94% (Interest Expense 910.0k / Debt 30.9m)
Taxrate = -0.09% (negative due to tax credits) (52.0k / -55.2m)
NOPAT = -133.6m (EBIT -133.5m * (1 - -0.09%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 32.11 (Total Current Assets 661.6m / Total Current Liabilities 20.6m)
Debt / Equity = 0.05 (Debt 30.9m / totalStockholderEquity, last quarter 614.2m)
Debt / EBITDA = 0.72 (negative EBITDA) (Net Debt -96.4m / EBITDA -133.3m)
Debt / FCF = 0.71 (negative FCF - burning cash) (Net Debt -96.4m / FCF TTM -135.6m)
Total Stockholder Equity = 546.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -21.86% (Net Income -145.4m / Total Assets 665.1m)
RoE = -26.60% (Net Income TTM -145.4m / Total Stockholder Equity 546.5m)
RoCE = -23.20% (EBIT -133.5m / Capital Employed (Equity 546.5m + L.T.Debt 28.7m))
RoIC = -23.52% (negative operating profit) (NOPAT -133.6m / Invested Capital 567.9m)
WACC = 15.12% (E(3.22b)/V(3.25b) * Re(15.24%) + D(30.9m)/V(3.25b) * Rd(2.94%) * (1-Tc(-0.00)))
Discount Rate = 15.24% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 19.91%
Fair Price DCF = unknown (Cash Flow -135.6m)
EPS Correlation: 25.84 | EPS CAGR: 60.16% | SUE: 4.0 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
Additional Sources for IRON Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle